On the afternoon of December 19th, a seminar on clinical trial consensus and related issues sponsored by the Committee of Drug Clinical Trials of the Chinese Pharmacological Association was held at the Third Xiangya Hospital. Prof. Xiong Yuqing, Chairman of the Professional Committee for Clinical Trials of the Pharmacology Society of China, Prof. Liang Maozhi, Deputy Chairman, Prof. Liu Tangwei, Honorary President of the First Affiliated Hospital of Guangxi Medical University, Prof. Yuan Hong, Associate Dean of Xiangya Third Hospital, and Experts of the Drug Clinical Trial Institute More than 20 experts, including Party representatives, CRO representatives, legal personnel, and lawyers, attended the symposium. The meeting was chaired by Yang Guoping, director of the committee of the Committee of Clinical Trials of the Chinese Pharmacology Association and director of the Department of Scientific Research of the Third Xiangya Hospital.
Vice President Yuan Hong gave a welcome speech and welcomed the arrival of experts. He hoped that through this meeting, some problems found in clinical trials could be resolved and a common understanding of progress in drug clinical trials could be formed.
The chairperson of Xiong Yuqing’s contribution to the clinical trials of Chinese medicine for the long-term contribution of the Third Xiangya Hospital and the Deputy Dean Yuan Hong expressed their gratitude for the support of the Committee and gave a high degree of consensus to Professor Hong Hong’s clinical research on antihypertensive drugs. The evaluation stated that it has promoted the improvement of the technical level of China's drug clinical trials. She pointed out that at present, the technical specifications, policies, regulations, and related research technologies of Chinese drug clinical trials have been greatly improved. Under the excellent situation of development, many problems have also been highlighted. These issues require everyone to sit down and discuss properly, so that the clinical trials of drugs can gradually become more standardized and advance toward the international level. It is believed that with the efforts of everyone, some of the decisions of this meeting will become a milestone in promoting the development of drug clinical trials in China.
In the following meetings, the experts discussed the experts' consensus on drug clinical trial technical service contract, the ethical review consensus topic of drug clinical trials, and the expert consensus on the effectiveness evaluation of antihypertensive drug clinical research. Among them, the expert consensus on drug clinical trial technical service contract will become the first expert consensus in China's drug clinical trial work.